theMednetRegister

Rheumatology

Psoriasis   

Questions discussed in this category

How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics? 
3 Answers available
How do you approach managing nausea and GI side effects when initiating methotrexate?
3 Answers available
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
SLE manifestations include arthralgias and cytopenias which are stable. Previously did well on methotrexate, but developed GI side effects. HCQ is on ...
3 Answers available
Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?
3 Answers available
How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?
The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.
1 Answer available
How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?
What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?
2 Answers available
Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?
1 Answer available
Would you consider using a JAK inhibitor in combination with an IL 23 inhibitor in cases of severe psoriasis, psoriatic arthritis, or axial spondyloarthritis that is refractory to multiple biologic DMARDs?
2 Answers available
How do you manage patients on biologics peri-operatively?
Are there any medications that surgeons like discontinued before their procedure?
1 Answer available
What is your approach to using apremilast for psoriatic arthritis in patients with history of depression?
1 Answer available
Is it ever reasonable to switch to a different TNFi as opposed to switching to an agent in a different class in a case of TNFi induced lupus or psoriasis?
In other words, do we think of TNFi induced lupus and TNFi induced psoriasis as a drug effect or a class effect? 
1 Answer available
What treatment options are available for patients with spondyloarthritis who develop biologic-induced psoriasis?
1 Answer available
What is the preferred DMARD in active spondyloarthropathy with psoriasis and sacroiliitis features in the setting of treated hepatitis C with negative viral load?
In patients refractory to NSAIDs and sulfasalazine 
1 Answer available


Papers discussed in this category

Journal of psoriasis and psoriatic arthritis, 2019-04
TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.
Front Pharmacol, 2019 Mar 26
Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders.
Seminars in arthritis and rheumatism, 2010-12
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Clin Exp Rheumatol, 2012 Oct 17
Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
Inflamm Bowel Dis,
Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Am J Clin Dermatol,
Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
The Journal of rheumatology, 2012-01
Combination biologic treatment of refractory psoriasis and psoriatic arthritis.
JAAD Case Rep, 2019 Oct 10
Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis.
Clinical rheumatology, 1988 Sep
Treatment of psoriatic arthritis with sulphasalazine: a one year open study.
Journal of the American Academy of Dermatology, 1987 Apr
Gold therapy and its indications in dermatology. A review.
Journal of the American Academy of Dermatology, 2020 May 19
Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.
Annals of the rheumatic diseases, 2018-09
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Arthritis & rheumatology (Hoboken, N.J.), 2019-02
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
RMD open, 2020 Feb
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
Trials, 2022 Sep 05
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Annals of the rheumatic diseases, 2024 Mar 18
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Ann Rheum Dis, 2020 Dec 17
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
Expert review of anticancer therapy, 2009-01
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
Lancet Gastroenterol Hepatol, 2023 Feb 01
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Ann Rheum Dis, 2014 Feb 13
The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.
Annals of the rheumatic diseases, 2023 Oct 12
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.

Related Topics in Rheumatology

Copyright © 2024 theMednet
All Rights Reserved.